European Crohn’s and Colitis Organisation (ECCO) 2021

Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

Digestive Diseases Week (DDW) 2021

Effect of etrasimod on circulating lymphocyte subsets: data from a randomized phase 1 study in healthy Japanese and Caucasian men

United European Gastroenterology (UEG) Week 2020

Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod (APD334) in the Randomised, Double Blind, Placebo Controlled, Phase 2 OASIS Trial and Open Label Extension

American College of Gastroenterology Annual Scientific Meeting (ACG) 2020

Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod (APD334) in the Randomized, Double Blind, Placebo Controlled Phase 2 OASIS Trial and Open Label Extension

Journal of Crohn’s & Colitis

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

European Crohn’s and Colitis Organisation (ECCO) 2020

Patient-Reported Disease Activity in a Large Sample of Ulcerative Colitis (UC) Patients Using Social Media-Delivered Questionnaires

Pharmacokinetics and Circulating Total Lymphocyte Count Pharmacodynamic Response From Single and Multiple Oral Doses of Etrasimod in Japanese and Caucasian Healthy Male Subjects 

Fecal Calprotectin and C-Reactive Protein Levels Are Correlated With Long-Term Clinical and Endoscopic Outcomes: Analysis of the OASIS Open-Label Extension Trial of Etrasimod for Ulcerative Colitis 

AAPS PHARMSCI 360 Meeting 2019

Mass Balance, Metabolic Disposition, and Pharmacokinetics of [14C]Etrasimod Following Oral Administration to Healthy Male Volunteers

1 2

For Medical Information, contact us at medinfo@arenapharm.com